title: Enoxacin compared with vancomycin for the treatment of experimental methicillin-resistant Staphylococcus aureus endocarditis.
abstract: Enoxacin administered orally was compared with vancomycin administered intravenously for the treatment of experimental methicillin-resistant Staphylococcus aureus endocarditis. The MICs and MBCs of both enoxacin and vancomycin for an inoculum of 5.0 X 10(5) CFU of the methicillin-resistant S. aureus strain per ml were 1.56 microgram/ml. With an inoculum of 10(8) CFU/ml, enoxacin at 6 micrograms/ml and vancomycin at 180 micrograms/ml resulted in similar decreases in numbers of methicillin-resistant S. aureus in broth. Methicillin-resistant S. aureus endocarditis in rabbits was treated with enoxacin at 100 mg/kg orally every 12 h or vancomycin at 30 mg/kg intravenously every 12 h for 3 or 5 days. Enoxacin treatment for 3 or 5 days and vancomycin treatment for 5 days significantly reduced bacterial counts of vegetations compared with those in untreated control rabbits after 1 day of infection. Bacterial counts of vegetations after vancomycin treatment for 3 days did not differ significantly from those of untreated controls. Bacterial counts of vegetations in the four therapeutic groups did not differ significantly from one another. In uninfected rabbits single doses of vancomycin at 30 mg/kg administered intravenously achieved much higher concentrations in serum than did single doses of enoxacin at 100 mg/kg administered orally. Enoxacin had an elimination half-life in serum that was approximately 1.5 times longer than that of vancomycin. This study demonstrated that enoxacin administered orally is as effective as vancomycin administered intravenously for the treatment of experimental methicillin-resistant S. aureus endocarditis.
authors.forename: M
authors.initials: M
authors.lastname: Gilbert
authors.forename: J A
authors.initials: JA
authors.lastname: Boscia
authors.forename: W D
authors.initials: WD
authors.lastname: Kobasa
authors.forename: D
authors.initials: D
authors.lastname: Kaye
mesh_terms: D000818:Animals; D000890:Anti-Infective Agents / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use*; D004697:Endocarditis, Bacterial / Q000188:drug therapy* / Q000209:etiology; D015365:Enoxacin; D005260:Female; D006207:Half-Life; D008712:Methicillin / Q000494:pharmacology*; D009287:Naphthyridines / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use*; D010403:Penicillin Resistance; D011817:Rabbits; D013203:Staphylococcal Infections / Q000188:drug therapy*; D014640:Vancomycin / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D000890:Anti-Infective Agents; D009287:Naphthyridines; D015365:Enoxacin; D014640:Vancomycin; D008712:Methicillin